Wells Fargo Starts Omnicell (OMCL) at Market Perform
Tweet
Share
E-mailGet Alerts OMCL Hot Sheet
Price: $27.11 -1.17%
Rating Summary:
9 Buy, 8 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 10 | Down: 12 | New: 7
Rating Summary:
9 Buy, 8 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 10 | Down: 12 | New: 7
Join SI Premium – FREE
Wells Fargo initiates coverage on Omnicell (NASDAQ: OMCL) with a Market Perform and $18-$20 valuation target.
The firm comments, "The company has an estimated 25% share of the market for selling medication dispensing cabinets and related software to hospitals in the United States. More recently, it has expanded into equipment and consumables that institutional pharmacies use to package medications that are dispensed in long term care facilities. While we project organic top line growth around 10% and believe management may be downplaying the accretion from the recent acquisition of MTS, these shares have bounced significantly off of recent lows and the company is exposed to hospital capital spending that could be impacted in the event that the economy falls off the fiscal cliff. We prefer to wait for a better buying opportunity or more certainty around economic conditions."
For an analyst ratings summary and ratings history on Omnicell click here. For more ratings news on Omnicell click here.
Shares of Omnicell closed at $15.82 yesterday.
The firm comments, "The company has an estimated 25% share of the market for selling medication dispensing cabinets and related software to hospitals in the United States. More recently, it has expanded into equipment and consumables that institutional pharmacies use to package medications that are dispensed in long term care facilities. While we project organic top line growth around 10% and believe management may be downplaying the accretion from the recent acquisition of MTS, these shares have bounced significantly off of recent lows and the company is exposed to hospital capital spending that could be impacted in the event that the economy falls off the fiscal cliff. We prefer to wait for a better buying opportunity or more certainty around economic conditions."
For an analyst ratings summary and ratings history on Omnicell click here. For more ratings news on Omnicell click here.
Shares of Omnicell closed at $15.82 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Wells Fargo Upgrades Neurocrine Bio. (NBIX) to Overweight 'as the Company is Knocking on the Doors of the Large-Cap Club'
- Wells Fargo Starts Americold Realty Trust (COLD) at Equal Weight
- Wells Fargo Upgrades Five Below (FIVE) to Overweight 'on Compelling Risk/Reward'
Create E-mail Alert Related Categories
New CoverageRelated Entities
Wells FargoSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
